Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50


Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

O'Connell RJ, Excler JL, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Liu M, Wieczorek L, McNeil JG, El-Habib R, Michael NL, Gilliam BL, Paris R, VanCott TC, Tomaras GD, Birx DL, Robb ML, Kim JH.

J Infect Dis. 2016 Jun 15;213(12):1946-54. doi: 10.1093/infdis/jiw059. Epub 2016 Feb 11.


The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators.

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.


Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148).

Ministry of Public Health-Thai AIDS Vaccine Evaluation Group.

Vaccine. 2011 Jun 6;29(25):4285-92. doi: 10.1016/j.vaccine.2011.03.014. Epub 2011 Mar 22.


Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators.

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.


Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.

Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, Lievens M, Vekemans J, Sigauque B, Dubois MC, Demoitié MA, Sillman M, Savarese B, McNeil JG, Macete E, Ballou WR, Cohen J, Alonso PL.

Lancet. 2007 Nov 3;370(9598):1543-51. Epub 2007 Oct 18.


A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH; Thai AIDS Vaccine Evaluation Group.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55.


Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping.

Watanaveeradej V, Benenson MW, Souza MD, Sirisopana N, Nitayaphan S, Tontichaivanich C, Amphaipit R, Renzullo PO, Brown AE, McNeil JG, Robb ML, Birx DL, Tovanabutra S, Carr JK, McCutchan FE.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):801-7.


Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.

Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS; Thai AIDS Vaccine Evaluation Group, Thailand.

Vaccine. 2005 Mar 31;23(19):2522-9.


HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting.

Paris R, Bejrachandra S, Karnasuta C, Chandanayingyong D, Kunachiwa W, Leetrakool N, Prakalapakorn S, Thongcharoen P, Nittayaphan S, Pitisuttithum P, Suriyanon V, Gurunathan S, McNeil JG, Brown AE, Birx DL, de Souza M.

Tissue Antigens. 2004 Sep;64(3):251-6.


Policy rebuttal. HIV vaccine trial justified.

McNeil JG, Johnston MI, Birx DL, Tramont EC.

Science. 2004 Feb 13;303(5660):961. No abstract available.


A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand.

Tovanabutra S, Watanaveeradej V, Viputtikul K, De Souza M, Razak MH, Suriyanon V, Jittiwutikarn J, Sriplienchan S, Nitayaphan S, Benenson MW, Sirisopana N, Renzullo PO, Brown AE, Robb ML, Beyrer C, Celentano DD, McNeil JG, Birx DL, Carr JK, McCutchan FE.

AIDS Res Hum Retroviruses. 2003 Jul;19(7):561-7.


Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J, de Souza M, Chuenchitra T, Garner RP, Thapinta D, Polonis V, Ratto-Kim S, Chanbancherd P, Chiu J, Birx DL, Duliege AM, McNeil JG, Brown AE; Thai AIDS Vaccine Evaluation Group.

J Infect Dis. 2003 Jul 15;188(2):219-27. Epub 2003 Jul 3.


HIV-1 infection among civilian applicants for US military service, 1985 to 2000: epidemiology and geography.

Sateren WB, Renzullo PO, Carr JK, Birx DL, McNeil JG.

J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):215-22.


Heterosexually acquired CRF01_AE/B recombinant HIV type 1 found in Thailand.

Viputtijul K, de Souza M, Trichavaroj R, Carr JK, Tovanabutra S, McCutchan FE, Sriplienchan S, Buapunth P, Chuenchitra C, McNeil JG, Birx DL, Brown AE, Nitayaphan S.

AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1235-7.


HIV-1 seroconversion in United States Army active duty personnel, 1985-1999.

Renzullo PO, Sateren WB, Garner RP, Milazzo MJ, Birx DL, McNeil JG.

AIDS. 2001 Aug 17;15(12):1569-74.


Clinical prognosis of patients with early-stage human immunodeficiency virus (HIV) disease: contribution of HIV-1 RNA and T lymphocyte subset quantitation.

Brown AE, Dolan MJ, Michael NL, Zhou S, Perfetto SP, Hawkes C, Robb M, Lane J, Mayers D, McNeil JG, Malone JD, Garner R, Birx DL; RGP160 Phase IIA Vaccine Investigators.

Mil Med. 2001 Jul;166(7):571-6.


A comparative study of the impact of HIV infection on natural killer cell number and function in Thais and North Americans.

de Souza MS, Karnasuta C, Brown AE, Markowitz LE, Nitayaphan S, Garner RP, McNeil JG, Birx DL, Cox JH.

AIDS Res Hum Retroviruses. 2000 Jul 20;16(11):1061-6.


Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand.

McCutchan FE, Viputtigul K, de Souza MS, Carr JK, Markowitz LE, Buapunth P, McNeil JG, Robb ML, Nitayaphan S, Birx DL, Brown AE.

AIDS Res Hum Retroviruses. 2000 May 20;16(8):801-5.


A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.

Nitayaphan S, Khamboonruang C, Sirisophana N, Morgan P, Chiu J, Duliege AM, Chuenchitra C, Supapongse T, Rungruengthanakit K, deSouza M, Mascola JR, Boggio K, Ratto-Kim S, Markowitz LE, Birx D, Suriyanon V, McNeil JG, Brown AE, Michael RA.

Vaccine. 2000 Feb 14;18(15):1448-55.


Evaluation of behavioral and social issues among Thai HIV vaccine trial volunteers.

Thapinta D, Jenkins RA, Celentano DD, Nitayaphan S, Buapunth P, Triampon A, Morgan PA, Khamboonruang C, Suwanarach C, Yutabootr Y, Ruckphaopunt S, Suwankiti S, Tubtong V, Cheewawat W, McNeil JG, Michael RA.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):308-14.


Supplemental Content

Loading ...
Support Center